Skip to main content

Table 2 Baseline characteristics among breast cancer subtypes, n(%)

From: Integration of breast cancer care in a middle-income country: learning from Suandok Breast Cancer Network (SBCN)

Variables Total Cohort 1 Cohort 2 P-valuea
Number of patients 3868 1485 2383
Age (year) < 0.001
 < 40 445 (11.4) 204 (13.8) 241 (10.1)
 40–60 2589 (67.0) 1028 (69.2) 1561 (65.5)
 > 60 834 (21.6) 253 (17.0) 581 (24.4)
Stage < 0.001
 I 586 (15.1) 206 (13.9) 380 (15.9)
 II 1553 (40.1) 621 (41.8) 932 (39.1)
 III 831 (21.5) 275 (18.5) 556 (23.4)
 IV 265 (6.8) 97 (6.5) 168 (7.0)
Unknown 633 (16.4) 286 (19.2) 347 (14.6)
Chemotherapy < 0.001
 No 1178 (30.4) 399 (26.9) 779 (32.7)
 Yes 2690 (69.5) 1086 (73.1) 1604 (67.3)
Chemotherapy Regimens < 0.001
 CMF 161 (6.0) 142 (13.1) 19 (1.2)
 FAC/FEC/AC 1930 (71.7) 840 (77.4) 1090 (67.9)
 AC-T 599 (22.3) 104 (9.6) 495 (30.9)
Radiotherapy     0.03
 No 1794 (46.4) 722 (48.6) 1072 (45.0)
 Yes 2074 (53.6) 763 (51.4) 1311 (55.0)
Hormonal therapy < 0.001
 No 1772 (45.8) 770 (51.8) 1002 (42.0)
 Yes 2096 (54.2) 715 (48.1) 1381 (58.0)
Hormonal therapy agent < 0.001
 Tamoxifen 1335 (75.2) 583 (86.6) 752 (68.3)
 Aromatase Inhibitor 439 (24.8) 90 (13.4) 349 (31.7)
  1. CMF Cyclophosphamide, methotrexate, and fluorouracil; FAC Fluorouracil, anthracycline, and cyclophosphamide; FEC Fluorouracil, epirubicin, and cyclophosphamide; AC Anthracycline and cyclophosphamide; AC-T Anthracycline, cyclophosphamide, and taxane
  2. aChi-square test